Understanding Pituitary Carcinoma (Metastatic PitNET)

Finding out that a pituitary tumor has spread can be overwhelming, especially when the condition is as rare as this one. Understanding the nature of this diagnosis and how it differs from other pituitary tumors is the first step in navigating your care.

A Change in Terminology

In 2022, the World Health Organization (WHO) updated its classification of pituitary tumors ^[1]. The preferred technical term for Pituitary Carcinoma is now Metastatic Pituitary Neuroendocrine Tumor, or Metastatic PitNET ^[1][2].

While “Metastatic PitNET” is favored in the new classification, many doctors and patients still use the term “Pituitary Carcinoma” ^[1]. This is a terminology change, not a newly defined disease. Both terms describe the same condition: a pituitary tumor that has demonstrated metastatic spread.

Defining the Diagnosis

The diagnosis of a metastatic PitNET is unique because it is not based on how the tumor cells look under a microscope ^[1]. Instead, it requires documented metastasis—the spread of the tumor to areas outside of the immediate pituitary region ^[2]. Confirmation may use imaging, CSF testing, biopsy, or a combination of clinical findings, depending on the site.

A tumor is classified as metastatic if it spreads to:

• The Craniospinal Axis: This includes the brain, the spinal cord, or the cerebrospinal fluid (CSF) via leptomeningeal spread ^[3][4].
• Systemic Sites: This refers to organs outside of the central nervous system, most commonly the bones, liver, or lungs ^[3][4].

Even if a tumor is very large, grows quickly, or directly invades nearby structures like the cavernous or sphenoid sinuses, this is considered local invasion. It is not considered a carcinoma unless it has physically moved to a distant site ^[2].

Understanding Rarity and Latency

Metastatic PitNETs are exceptionally rare, accounting for only 0.1% to 0.2% of all pituitary tumors ^[5][6]. Because of this rarity, many local hospitals or general oncologists may have never treated a patient with this specific condition. Seeking care at a major medical center with a specialized pituitary team is often recommended to ensure you have access to doctors with specific experience ^[7][8].

One of the most striking features of this condition is the latency period—the amount of time between the first diagnosis of a pituitary tumor and the discovery of a metastasis. In specific historical cohorts, this interval averaged about 9 years, though it can range significantly ^[5][9]. This means that a tumor that appeared benign and was stable for many years can eventually develop the ability to spread ^[6].

Common Sites of Spread

When a PitNET does spread, it often moves through the CSF or the bloodstream ^[3]. Findings from specific literature reviews have shown that:

• The central nervous system (brain and spine) is the most common site of metastasis ^[3].
• Bone is the most frequent site for spread outside of the brain and spine ^[3].
• The liver and lungs are also documented sites for systemic spread ^[4].

(Note: These figures represent trends in study cohorts, and an individual patient’s metastatic pattern may differ).

Multidisciplinary Care

Because metastatic PitNETs are complex, the European Society of Endocrinology (ESE) and other expert groups recommend a multidisciplinary team approach ^[7]. This team typically includes:

• Endocrinologists: To manage hormone levels and their effects on your body ^[10].
• Neurosurgeons: To evaluate if surgery can help decompress nerves or remove metastatic lesions ^[8].
• Radiation Oncologists: To target specific areas of tumor growth ^[11].
• Neuro-oncologists: To manage systemic treatments like Temozolomide, an oral chemotherapy drug that is often the first-line medical treatment for this condition ^[7][8].

A Note on Treatment

Management is highly individualized based on the type of hormones the tumor produces and where it has spread ^[8]. While Temozolomide is a common first-line systemic therapy, other emerging options like PRRT (Peptide Receptor Radionuclide Therapy) or immune checkpoint inhibitors may be considered if standard treatments are not effective ^[12][13]. These newer therapies are often accessed through clinical trials or specialized centers ^[14][15].

Potential Complications

Treatments for metastatic PitNETs carry risks that your team will monitor closely. Surgery can sometimes lead to diabetes insipidus (an imbalance of fluids) or hyponatremia (low sodium levels), while radiation can affect the function of the healthy parts of the pituitary gland ^[16][11]. Your care team will create a surveillance plan to manage these risks while focusing on controlling the tumor’s growth ^[7].